Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2000-09-09
2003-03-04
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S093100, C424S093200, C424S187100, C424S188100, C424S009200, C435S069100, C435S091330, C345S536000, C345S023000
Reexamination Certificate
active
06528250
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a method for infecting equines with equine infectious anemia (EIA) in order to reproduce a natural infection challenge model comprising administering at least 1 median horse infective dose (MHID) to an equine, preferably on a repeated basis via an intravenous route. The model can be used for testing vaccines for their ability to protect equines from EIA, drugs or other treatments that can be used to treat equines infected with EIA or diagnostic procedures for detection of the EIA status of an equine.
2. Brief Description of the Prior Art
The equine infectious anemia virus is a member of the lentivirus subfamily of retroviruses and causes persistent infection and chronic disease in horses worldwide. As such, it is closely related to human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV) and feline immunodeficiency virus (FIV). As with HIV and SIV, disease caused by EIAV is spread by blood transmission. With EIAV, the blood transmission most often occurs by biting flies and other insects carrying virus particles from one horse to another. The first cycle of disease (clinical episode or first febrile episode) in an infected horse usually occurs within 42 days after transmission of the virus. This first cycle is usually characterized by the acute stage of EIA and manifested by pyrexia, thrombocytopenia, anorexia, depression and high plasma viremia levels. Anemia is not usually detected at this stage. Resolution of this first febrile episode is normally observed after 1 to 5 days and occurs concomitantly with a dramatic drop in the amount of plasma-associated virus. Following the acute stage, some animals may remain clinically normal, while others go on to experience multiple bouts of illness in which severe anemia may accompany pyrexia, thrombocytopenia, edema, and dramatic weight loss, and death. Nucleotide sequence data has revealed a high mutation rate of this lentivirus genome during persistent infection (Payne et al, Virology, 1987: 161, pp 321-331) incorporated herein by reference. It is generally known that multiple isolates from the field demonstrate similar genomic differences indicating that EIAV, as HIV and FIV, undergoes a continuing mutation process within its various hosts. It is generally thought that neutralizing antibodies aid in the selection of new antigenic virus variants (mutations) during persistent infections. In infections with EIAV, serologically distinct variants emerge possibly through immune selection pressure operating on random viral genome mutations. It is proposed that horses that show no further clinical signs of disease have developed a mature immune response that can contain the virus and its immunologically-recognized mutants.
The disease is significant because horses that demonstrate exposure to EIAV via testing for antibodies in the blood (Coggins Test or similar anti-p26 antibody detecting test) are required to be destroyed or strictly quarantined. Because of the Coggins Test and its broad use in the world, especially in testing all performance horses that are transferred into and out of the United States, it is critical that vaccinated equines be able to be differentiated from infected equines.
In testing vaccines, treatments or diagnostics for EIA it is imperative that clinical disease can be reproduced in equids. Previously, Issel et al (J. Virol June 1992, pp 3398-3408) attempted to test vaccines comprising purified env proteins from the equine infectious anemia virus (EIAV) for use as vaccines. The equid model used involved challenge of ponies with 300 median equine infectious doses (MEID) of pathogenic EIAV. There was no protection with heterologous strains of EIAV. In fact, this test demonstrated that these vaccines produced an enhanced disease when the ponies were challenged with a heterologous EIAV strain. Since all the previous work involved use of ponies and use of high challenge doses, there was no information on whether horses could be infected with EIAV, whether horses would develop clinical signs of EIA or whether a dose of 300 MEIDs was too high or too low for horses.
In order to understand how the model in the present invention can be used, it important to understand the genetic organization of EIAV. Therefore, a summary explanation follows.
The genetic organization of EIAV, as with HIV, SIV and FIV contains only three accessory genes (S1, S2 and S3), in addition to the gag, pol and env genes common to all retroviruses. The S1 open reading frame (ORF) encodes the viral Tat protein, a transcription trans activator that acts on the viral long-terminal-repeat (LTR) promoter element to stimulate expression of all viral genes. The S3 ORF encodes a Rev protein, a post-transcriptional activator that acts by interacting with its target RNA sequence, named the Rev-responsive element (RRE), to regulate viral structural gene expression. The S2 gene is located in the pol-env intergenic region immediately following the second exon of Tat and overlapping the amino terminus of the Env protein (see
FIGS. 1
,
2
a
and
2
b
). It encodes a 65-amino-acid protein with a calculated molecular mass of 7.2 kDa, which is in good agreement with the size of an in vitro translation product. S2 appears to be synthesized in the late phase of the viral replication cycle by ribosomal leaky scanning of a tricistronic mRNA encoding Tat, S2 protein, and Env, respectively. The ORF coding for the S2 protein of EIAV is highly conserved in all published EIAV sequences and contains three potential functional motifs (
FIG. 2
a
): GLFG (putative nucleoporin motif), PXXP (putative SH3 domain binding motif) and RRKQETKK (putative nuclear localization sequence). Antibodies to S2 protein can be found in sera from experimentally and naturally infected horses, indicating that S2 is expressed during EIAV replication in vivo. These observations suggest that S2 is likely to perform an important role in the virus life cycle. A discussion of the function of S2 is found in Li et al (J. Virol., October 1998, p 8344-8348), incorporated herein by reference.
A second interesting gene contained within the lentivirus group codes for dUTPase. This enzyme catalyzes the conversion of dUTP to dUMP and pp
i
. The gene encoding the dUTPase has been mapped within the pol gene for EIAV and FIV. The lentivirus dUTPase gene has been designated DU. Studies with DU deletion mutants (&Dgr;DU) of EIAV and FIV show that this enzyme is not required for replication of the viruses in fetal equine kidney cells or Crandell cells. However, efficient replication of the EIAV or FIV in monocyte/macrophage cells (typical replication host cell) does require DU. The differences indicated have been described in detail in a publication by Lichtenstein et al (J. Virol., May 1995, p 2881-2888), incorporated herein by reference.
Envelope proteins (env) are thought to be required for protection from disease and, perhaps, protection from infection. By protection from disease is meant that a mammal exposed to the virus, does not demonstrate clinical signs (fever, lethargy, anemia, etc.) but does carry particles associated with the viral RNA genome (shortened herein to viral particles) in its blood, said particles being detectable by a reverse transcriptase polymerase chain reaction test (RT-PCR). By protection from infection is meant that a mammal exposed to the virus does not demonstrate clinical signs nor does its blood contain RT-PCR-detectable virus particles as described above. The major envelope proteins of EIAV are gp90 and gp45. These are proposed as the protective antigens of EIAV. By the term protective antigens is meant antigens from EIAV that produce either protection from disease or protection from infection as indicated above.
Since there have been no reports of challenge models in which EIA can be reproduced in horses such that the natural infection is reproduced, there has been no effective method for testing vaccines, treatments or diagnostics.
REFERENCES:
Harrold et al. J. Virol. 2000, vol. 74, pp. 311
Brown Karen K.
Hennessey Kristina J.
Issel Charles
Li Feng
Montelaro Ronald
Akzo Nobel N.V.
Blackstone William M.
Li Bao Qun
Ramey III William P.
Salimi Ali R.
LandOfFree
Equine infectious anemia challenge model for testing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Equine infectious anemia challenge model for testing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Equine infectious anemia challenge model for testing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3076849